Literature DB >> 73062

Treatment of acute viral hepatitis with (+)-cyanidanol-3.

A L Blum, P Berthet, W Doelle, H Goebell, K Kortüm, S Pelloni, P Peter, H Poulsen, G Strohmeyer, N Tygstrup.   

Abstract

A double-blind trial of (+)-cyanidanol-3 (2 g/day) versus placebo tablets was carried out in 100 patients with acute viral hepatitis. 51 received the drug and 49 placebo. (+)-Cyanidanol-3 accelerated the disappearance of HBsAg from the blood, lowered serum-bilirubin, and relieved symptoms such as anorexia, nausea, and pruritus. The drug was well tolerated. None of the patients had a relapse of acute hepatitis. Chronic active hepatitis developed in 1 of the placebo-treated patients. Thus, (+)-cyanidanol-3 seems to be of benefit in acute viral hepatitis.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 73062     DOI: 10.1016/s0140-6736(77)91540-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  13 in total

1.  Transfer factor and hepatitis B: a double blind study.

Authors:  R Ellis-Pegler; D C Sutherland; R Douglas; D G Woodfield; J D Wilson
Journal:  Clin Exp Immunol       Date:  1979-05       Impact factor: 4.330

2.  Suppression of delayed-type hypersensitivity mediated by macrophage-like cells in mice with experimental liver injury.

Authors:  S Tajima; N Nishimura; K Ito
Journal:  Immunology       Date:  1985-01       Impact factor: 7.397

3.  (+)-Cyanidanol-3 as inhibitor of prostaglandin synthetase. Studies on renal medulla and liver of the rat in vitro and in vivo.

Authors:  J Baumann; F von Bruchhausen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-01       Impact factor: 3.000

4.  The pathogenesis of cianidanol-induced fever.

Authors:  P T Daniel; J Holzschuh; P A Berg
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Effect of (+)-cyanidanol-3 on chronic active hepatitis: a double blind controlled trial.

Authors:  S Bar-Meir; Z Halpern; M Gutman; Z Shpirer; M Baratz; D Bass
Journal:  Gut       Date:  1985-09       Impact factor: 23.059

6.  Influence of (+)-cyanidanol-3 on the leukocyte migration inhibition test carried out in the presence of purified protein derivative and hepatitis B surface antigen.

Authors:  J J Vallotton; P C Frei
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

7.  Trial of (+)-cyanidanol-3 in patients with hepatitis B chronic liver disease.

Authors:  P W Keeling; L Viola; M G Anderson; J H Marigold; J C Macartney; F J Paradinas; I M Murray-Lyon; R P Thompson
Journal:  J R Soc Med       Date:  1986-08       Impact factor: 5.344

8.  Protection of mice against endotoxin-induced liver damage by anti-inflammatory drugs.

Authors:  J Ferluga; A Kaplun; A C Allison
Journal:  Agents Actions       Date:  1979-12

9.  Identification of the major urinary metabolites of (+)-catechin and 3-O-methyl-(+)-catechin in man.

Authors:  M Wermeille; E Turin; L A Griffiths
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983       Impact factor: 2.441

10.  3'-O-methyl-(+)-catechin glucuronide and 3'-O-methyl-(+)-catechin sulphate: new urinary metabolites of (+)-catechin in the rat and the marmoset.

Authors:  A M Hackett; I C Shaw; L A Griffiths
Journal:  Experientia       Date:  1982-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.